The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

Explore the current issue of The New England Journal of Medicine (Vol. 394 No. 11).

The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care.

Mar 11, 2026 · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

Index of all Issues from New England Journal of Medicine

The New England Journal of Medicine (NEJM) is recognized as the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed ...

Mar 6, 2026 · Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, induces potent B-cell depletion and is approved for the treatment of active lupus nephritis. Its efficacy and safety in …

Dec 9, 2025 · In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated …

Dec 17, 2025 · We conducted an active-comparator–controlled, double-blind, noninferiority trial in which patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomly assigned in …

Feb 4, 2026 · Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; …